Lv11
40 积分 2023-06-25 加入
Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
4小时前
已完结
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial
25天前
已完结
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
25天前
已完结
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study
25天前
已完结
2014年中国恶性肿瘤发病和死亡分析
1个月前
已完结
Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
3个月前
已完结
Bruton’s tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system
3个月前
已关闭
Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of central nervous system
3个月前
已关闭
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
5个月前
已完结
CAR T‐cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real‐life results of the LOC network
5个月前
已完结
皖公网安备34019202002308
